Therapeutics: Diacylglycerol kinase α (DGKα); SH2 domain containing 1A (SH2D1A); T cell receptor (TCR)

Patient sample and mouse studies suggest inhibiting DGKα could help treat X-linked lymphoproliferative disorder (XLP-1). The disorder is caused by mutations in SH2D1A, a negative regulator of DGKα, th...